Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Masimo Corporation (MASI) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Masimo Corporation (MASI) lobbying for?
Summary of Lobbying Data:
Masimo Corporation has hired three lobbying firms, including themselves, for their 10 most recent lobbying contracts. They have lobbied on a variety of general issues, including taxation, labor issues, health issues, immigration, consumer issues, and copyright/patent/trademark. Furthermore, they have lobbied on specific issues such as patient safety, anti-competitive behavior in the medical device supply chain, Medicare coverage and reimbursement, and intellectual property policy. The company has lobbied government agencies such as the Office of Natl Drug Control Policy, the Patent & Trademark Office, the White House Office, the Department of Health & Human Services, the Senate, and the Executive Office of the President.
Inference about Why Masimo Corporation is Lobbying:
One could infer that Masimo Corporation is lobbying on such a wide range of issues to protect their interests as a medical device manufacturing company. Issues such as patient safety, anti-competitive behavior, and Medicare coverage would directly impact their business operations. The company is likely seeking regulatory oversight of antitrust violations/anticompetitive behavior to protect their position in the medical device supply chain. They are also lobbying for patent reform legislation and proposals as well as pro-inventor intellectual property policy to safeguard their technological advancements. Additionally, Masimo Corporation is advocating for the use of medical technology for monitoring patients taking opioids for pain management, which may align with their focus on patient safety and innovation in medical devices. Overall, the company’s lobbying efforts seem to be centered around protecting their business interests and promoting technological advancements in the healthcare industry.
